Anzeige
Mehr »
Login
Freitag, 14.08.2020 Börsentäglich über 12.000 News von 644 internationalen Medien
News des Tages: Produkt nach 72 Stunden komplett ausverkauft!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0CBCK ISIN: US02043Q1076 Ticker-Symbol: DUL 
Tradegate
12.08.20
21:22 Uhr
116,48 Euro
-0,04
-0,03 %
Branche
Pharma
Aktienmarkt
NASDAQ Biotech
1-Jahres-Chart
ALNYLAM PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
ALNYLAM PHARMACEUTICALS INC 5-Tage-Chart
RealtimeGeldBriefZeit
115,50117,3613.08.
115,46117,2013.08.

Aktuelle News zur ALNYLAM PHARMACEUTICALS Aktie

  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
07.08.Alnylam Managing Through Covid-19 Challenges And Executing Well7
07.08.Alnylam (ALNY) Beats on Q2 Earnings, Narrows Sales Guidance7
07.08.Alexion creates new post for chief diversity officer; Barry Greene stepping down at Alnylam, Yvonne Greenstreet named as successor4
ALNYLAM PHARMACEUTICALS Aktie jetzt für 0€ handeln
06.08.Alnylam Pharmaceuticals, Inc (ALNY) CEO John Maraganore on Q2 2020 Results - Earnings Call Transcript4
06.08.Alnylam Pharmaceuticals, Inc. 2020 Q2 - Results - Earnings Call Presentation6
06.08.Alnylam president Barry Greene leaves after 17 years, handing position over to Yvonne Greenstreet as biotech looks toward profitability6
06.08.Alnylam Pharma Names Yvonne Greenstreet President & COO822WASHINGTON (dpa-AFX) - Alnylam Pharmaceuticals, Inc. (ALNY) announced that, Barry Greene, President, has decided to leave the company at the end of the third quarter. He will remain a consultant...
► Artikel lesen
06.08.Alnylam Pharmaceuticals Inc. Q2 adjusted earnings Beat Estimates157WASHINGTON (dpa-AFX) - Below are the earnings highlights for Alnylam Pharmaceuticals Inc. (ALNY):-Earnings: -$179.23 million in Q2 vs. -$219.48 million in the same period last year. -EPS:...
► Artikel lesen
06.08.ALNYLAM PHARMACEUTICALS, INC. - 10-Q, Quaterly Report1
06.08.ALNYLAM PHARMACEUTICALS, INC. - 8-K, Current Report2
03.08.Alnylam Submits CTA Application In UK To Start Phase 1 Trial Of ALN-HSD To Treat NASH231LONDON (dpa-AFX) - Alnylam Pharmaceuticals Inc. (ALNY) announced Monday that it has submitted a clinical trial authorization or CTA application in the United Kingdom for ALN-HSD, an investigational...
► Artikel lesen
03.08.Alnylam Submits CTA Application for ALN-HSD, an Investigational RNAi Therapeutic for the Treatment of Nonalcoholic Steatohepatitis (NASH)203- Company Expects to Initiate a Phase 1 Study in Late 2020 - Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the Company has submitted...
► Artikel lesen
14.07.COVID-19 Impact and Recovery Analysis - Global Biodefense Market 2020-2024 | Evolving Opportunities With Alexeter Technologies LLC and Alnylam Pharmaceuticals Inc. | Technavio198The global biodefense market is expected to grow by USD 3.22 billion as per Technavio. This marks a significant market growth compared to the 2019 growth estimates due to the impact of the COVID-19...
► Artikel lesen
13.07.UK regulator OK's early access to Alnylam's lumasiran5
09.07.Alnylam Pharmaceuticals und Taiba Group kooperieren beim Vertrieb von RNAi-Therapeutika in den Golfstaaten249Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), das führende Unternehmen für RNAi-Therapeutika, und taiba Middle East, ein führendes Unternehmen für seltene Krankheiten mit Sitz in den Vereinigten...
► Artikel lesen
08.07.Alnylam Pharma partners with Taiba Group to commercialize RNAi therapeutics in Gulf states-
08.07.BRIEF-Alnylam Pharmaceuticals And Taiba Group Partner To Commercialize RNAi Therapeutics In The Gulf States-
08.07.Alnylam Pharmaceuticals and Taiba Group Partner to Commercialize RNAi Therapeutics in the Gulf States219Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, and taiba Middle East, a leading rare disease company based in the United Arab Emirates and covering the Middle...
► Artikel lesen
30.06.BRIEF-Alnylam Reports New 12-Month Interim Data From The Envision Phase 3 Study Of Givosiran In Acute Hepatic Porphyria3
30.06.Alnylam's RNAi therapy Givlaari shows lasting effect one year into treatment, new data show5
Seite:  Weiter >>
140 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1